Enzymatica publ AB Total Liabilities
Enzymatica publ AB total liabilities. Based on the latest financial reports, Enzymatica publ AB (ENZY) has total liabilities worth Skr13.56 Million SEK (≈ $1.46 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Enzymatica publ AB (ENZY) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Enzymatica publ AB (2007–2024)
Total liabilities of Enzymatica publ AB from 2007 to 2024. This chart illustrates how Enzymatica publ AB's total liabilities have evolved over time, based on quarterly financial data. Explore ENZY long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Enzymatica publ AB Competitors by Total Liabilities
The table below lists competitors of Enzymatica publ AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
GIIB Holdings Bhd
KLSE:7192
|
Malaysia | RM67.48 Million |
|
Tenax Therapeutics Inc
NASDAQ:TENX
|
USA | $8.07 Million |
|
Mawana Sugars Limited
NSE:MAWANASUG
|
India | Rs5.98 Billion |
|
Korea Computer & Systems Inc
KQ:115500
|
Korea | ₩10.67 Billion |
|
L.P.N. Development Public Company Limited
BK:LPN
|
Thailand | ฿12.24 Billion |
|
Thitikorn Public Company Limited
BK:TK
|
Thailand | ฿367.52 Million |
|
Korea Business News Co. Ltd
KQ:039340
|
Korea | ₩24.41 Billion |
|
PowerBank Corporation
NASDAQ:SUUN
|
USA | $105.51 Million |
Liability Composition Analysis (2007–2024)
This chart breaks down Enzymatica publ AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ENZY total asset value.
Liquidity & Leverage Metrics
Enzymatica publ AB Total Liabilities Ratios Explained
Enzymatica publ AB total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.25 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 2.47 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Enzymatica publ AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Enzymatica publ AB (2007–2024)
The table below shows the annual total liabilities of Enzymatica publ AB from 2007 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr18.86 Million ≈ $2.03 Million |
-61.76% |
| 2023-12-31 | Skr49.30 Million ≈ $5.31 Million |
+2.46% |
| 2022-12-31 | Skr48.12 Million ≈ $5.18 Million |
+50.06% |
| 2021-12-31 | Skr32.07 Million ≈ $3.45 Million |
-42.09% |
| 2020-12-31 | Skr55.38 Million ≈ $5.96 Million |
+94.26% |
| 2019-12-31 | Skr28.51 Million ≈ $3.07 Million |
+11.74% |
| 2018-12-31 | Skr25.51 Million ≈ $2.75 Million |
+10.33% |
| 2017-12-31 | Skr23.12 Million ≈ $2.49 Million |
+12.26% |
| 2016-12-31 | Skr20.60 Million ≈ $2.22 Million |
-5.80% |
| 2015-12-31 | Skr21.87 Million ≈ $2.35 Million |
+124.44% |
| 2014-12-31 | Skr9.74 Million ≈ $1.05 Million |
-5.32% |
| 2013-12-31 | Skr10.29 Million ≈ $1.11 Million |
+424.20% |
| 2012-12-31 | Skr1.96 Million ≈ $211.25K |
+47.59% |
| 2011-12-31 | Skr1.33 Million ≈ $143.13K |
-55.47% |
| 2010-12-31 | Skr2.99 Million ≈ $321.45K |
+40.67% |
| 2009-12-31 | Skr2.12 Million ≈ $228.51K |
+21.62% |
| 2008-12-31 | Skr1.75 Million ≈ $187.90K |
+87.94% |
| 2007-12-31 | Skr929.00K ≈ $99.98K |
-- |
About Enzymatica publ AB
Enzymatica AB (publ), a life science company, develops and sells medical devices for infection-related diseases. The company's product includes ColdZyme, a mouth spray that protects against the upper respiratory viruses that can cause cold and flu symptoms. It also provides enzyme formulations for skin care. The company was incorporated in 2007 and is headquartered in Lund, Sweden.